January 20, 2023
Article
The combination of zolbetuximab and mFOLFOX6 prolonged survival in patients with CLDN18.2+ advanced gastric gastroesophageal junction adenocarcinoma, according to the phase 3 data from the SPOTLIGHT trial.
January 19, 2023
Article
Findings from a phase 1/2 trial showed that sotigalimab plus pembrolizumab led to antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.
January 18, 2023
Article
Updated findings from the TACTI-002 trial of pembrolizumab and eftilagimod alpha in non–small cell lung cancer were presented during the Society for Immunotherapy of Cancer 37th Annual Meeting & Pre-Conference.
January 18, 2023
Article
According to findings from the phase 1 COBALT-RCC trial, CTX130 led to an objective response rate of 8%, a stable disease rate of 69%, and a disease control rate of 77% in patients with advanced clear cell renal cell carcinoma.
December 12, 2022
Article
The MOMENTUM trial continues to show positive results for momelotinib fro the treatment of anemic myelofibrosis.
December 10, 2022
Article
Olverembatinib is efficacious and well tolerated in tyrosine kinase inhibitor-resistant CML-CP and CML-AP patients with a BCR-ABL1 T315I mutation.